American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer

David G. Pfister, Scott A. Laurie, Gregory S. Weinstein, William M. Mendenhall, David J. Adelstein, K. Kian Ang, Gary L. Clayman, Susan G. Fisher, Arlene A. Forastiere, Louis B. Harrison, Jean Louis Lefebvre, Nancy Leupold, Many A. List, Bernard O. O'Malley, Snehal Patel, Marshall R. Posner, Michael A. Schwartz, Gregory T. Wolf

Research output: Contribution to journalArticle

Abstract

Purpose: To develop a clinical practice guideline for treatment of laryngeal cancer with the intent of preserving the larynx (either the organ itself or its function). This guideline is intended for use by oncologists in the care of patients outside of clinical trials. Methods: A multidisciplinary Expert Panel determined the clinical management questions to be addressed and reviewed the literature available through November 2005, with emphasis given to randomized controlled trials of site-specific disease. Survival, rate of larynx preservation, and toxicities were the principal outcomes assessed. The guideline underwent internal review and approval by the Panel, as well as external review by additional experts, members of the American Society of Clinical Oncology (ASCO) Health Services Committee, and the ASCO Board of Directors. Results: Evidence supports the use of larynx-preservation approaches for appropriately selected patients without a compromise in survival; however, no larynx-preservation approach offers a survival advantage compared with total laryngectomy and adjuvant therapy with rehabilitation as indicated. Recommendations: All patients with T1 or T2 laryngeal cancer, with rare exception, should be treated initially with intent to preserve the larynx. For most patients with T3 or T4 disease without tumor invasion through cartilage into soft tissues, a larynx-preservation approach is an appropriate, standard treatment option, and concurrent chemoradiotherapy therapy is the most widely applicable approach. To ensure an optimum outcome, special expertise and a multidisciplinary team are necessary, and the team should fully discuss with the patient the advantages and disadvantages of larynx-preservation options compared with treatments that include total laryngectomy.

Original languageEnglish (US)
Pages (from-to)3693-3704
Number of pages12
JournalJournal of Clinical Oncology
Volume24
Issue number22
DOIs
StatePublished - Aug 1 2006
Externally publishedYes

Fingerprint

Laryngeal Neoplasms
Larynx
Practice Guidelines
Laryngectomy
Therapeutics
Guidelines
Survival
Medical Oncology
Chemoradiotherapy
Health Services
Cartilage
Patient Care
Rehabilitation
Survival Rate
Randomized Controlled Trials
Clinical Trials
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pfister, D. G., Laurie, S. A., Weinstein, G. S., Mendenhall, W. M., Adelstein, D. J., Ang, K. K., ... Wolf, G. T. (2006). American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. Journal of Clinical Oncology, 24(22), 3693-3704. https://doi.org/10.1200/JCO.2006.07.4559

American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. / Pfister, David G.; Laurie, Scott A.; Weinstein, Gregory S.; Mendenhall, William M.; Adelstein, David J.; Ang, K. Kian; Clayman, Gary L.; Fisher, Susan G.; Forastiere, Arlene A.; Harrison, Louis B.; Lefebvre, Jean Louis; Leupold, Nancy; List, Many A.; O'Malley, Bernard O.; Patel, Snehal; Posner, Marshall R.; Schwartz, Michael A.; Wolf, Gregory T.

In: Journal of Clinical Oncology, Vol. 24, No. 22, 01.08.2006, p. 3693-3704.

Research output: Contribution to journalArticle

Pfister, DG, Laurie, SA, Weinstein, GS, Mendenhall, WM, Adelstein, DJ, Ang, KK, Clayman, GL, Fisher, SG, Forastiere, AA, Harrison, LB, Lefebvre, JL, Leupold, N, List, MA, O'Malley, BO, Patel, S, Posner, MR, Schwartz, MA & Wolf, GT 2006, 'American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer', Journal of Clinical Oncology, vol. 24, no. 22, pp. 3693-3704. https://doi.org/10.1200/JCO.2006.07.4559
Pfister, David G. ; Laurie, Scott A. ; Weinstein, Gregory S. ; Mendenhall, William M. ; Adelstein, David J. ; Ang, K. Kian ; Clayman, Gary L. ; Fisher, Susan G. ; Forastiere, Arlene A. ; Harrison, Louis B. ; Lefebvre, Jean Louis ; Leupold, Nancy ; List, Many A. ; O'Malley, Bernard O. ; Patel, Snehal ; Posner, Marshall R. ; Schwartz, Michael A. ; Wolf, Gregory T. / American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 22. pp. 3693-3704.
@article{e5f19557e3c0474084a3bee0515be2ad,
title = "American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer",
abstract = "Purpose: To develop a clinical practice guideline for treatment of laryngeal cancer with the intent of preserving the larynx (either the organ itself or its function). This guideline is intended for use by oncologists in the care of patients outside of clinical trials. Methods: A multidisciplinary Expert Panel determined the clinical management questions to be addressed and reviewed the literature available through November 2005, with emphasis given to randomized controlled trials of site-specific disease. Survival, rate of larynx preservation, and toxicities were the principal outcomes assessed. The guideline underwent internal review and approval by the Panel, as well as external review by additional experts, members of the American Society of Clinical Oncology (ASCO) Health Services Committee, and the ASCO Board of Directors. Results: Evidence supports the use of larynx-preservation approaches for appropriately selected patients without a compromise in survival; however, no larynx-preservation approach offers a survival advantage compared with total laryngectomy and adjuvant therapy with rehabilitation as indicated. Recommendations: All patients with T1 or T2 laryngeal cancer, with rare exception, should be treated initially with intent to preserve the larynx. For most patients with T3 or T4 disease without tumor invasion through cartilage into soft tissues, a larynx-preservation approach is an appropriate, standard treatment option, and concurrent chemoradiotherapy therapy is the most widely applicable approach. To ensure an optimum outcome, special expertise and a multidisciplinary team are necessary, and the team should fully discuss with the patient the advantages and disadvantages of larynx-preservation options compared with treatments that include total laryngectomy.",
author = "Pfister, {David G.} and Laurie, {Scott A.} and Weinstein, {Gregory S.} and Mendenhall, {William M.} and Adelstein, {David J.} and Ang, {K. Kian} and Clayman, {Gary L.} and Fisher, {Susan G.} and Forastiere, {Arlene A.} and Harrison, {Louis B.} and Lefebvre, {Jean Louis} and Nancy Leupold and List, {Many A.} and O'Malley, {Bernard O.} and Snehal Patel and Posner, {Marshall R.} and Schwartz, {Michael A.} and Wolf, {Gregory T.}",
year = "2006",
month = "8",
day = "1",
doi = "10.1200/JCO.2006.07.4559",
language = "English (US)",
volume = "24",
pages = "3693--3704",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "22",

}

TY - JOUR

T1 - American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer

AU - Pfister, David G.

AU - Laurie, Scott A.

AU - Weinstein, Gregory S.

AU - Mendenhall, William M.

AU - Adelstein, David J.

AU - Ang, K. Kian

AU - Clayman, Gary L.

AU - Fisher, Susan G.

AU - Forastiere, Arlene A.

AU - Harrison, Louis B.

AU - Lefebvre, Jean Louis

AU - Leupold, Nancy

AU - List, Many A.

AU - O'Malley, Bernard O.

AU - Patel, Snehal

AU - Posner, Marshall R.

AU - Schwartz, Michael A.

AU - Wolf, Gregory T.

PY - 2006/8/1

Y1 - 2006/8/1

N2 - Purpose: To develop a clinical practice guideline for treatment of laryngeal cancer with the intent of preserving the larynx (either the organ itself or its function). This guideline is intended for use by oncologists in the care of patients outside of clinical trials. Methods: A multidisciplinary Expert Panel determined the clinical management questions to be addressed and reviewed the literature available through November 2005, with emphasis given to randomized controlled trials of site-specific disease. Survival, rate of larynx preservation, and toxicities were the principal outcomes assessed. The guideline underwent internal review and approval by the Panel, as well as external review by additional experts, members of the American Society of Clinical Oncology (ASCO) Health Services Committee, and the ASCO Board of Directors. Results: Evidence supports the use of larynx-preservation approaches for appropriately selected patients without a compromise in survival; however, no larynx-preservation approach offers a survival advantage compared with total laryngectomy and adjuvant therapy with rehabilitation as indicated. Recommendations: All patients with T1 or T2 laryngeal cancer, with rare exception, should be treated initially with intent to preserve the larynx. For most patients with T3 or T4 disease without tumor invasion through cartilage into soft tissues, a larynx-preservation approach is an appropriate, standard treatment option, and concurrent chemoradiotherapy therapy is the most widely applicable approach. To ensure an optimum outcome, special expertise and a multidisciplinary team are necessary, and the team should fully discuss with the patient the advantages and disadvantages of larynx-preservation options compared with treatments that include total laryngectomy.

AB - Purpose: To develop a clinical practice guideline for treatment of laryngeal cancer with the intent of preserving the larynx (either the organ itself or its function). This guideline is intended for use by oncologists in the care of patients outside of clinical trials. Methods: A multidisciplinary Expert Panel determined the clinical management questions to be addressed and reviewed the literature available through November 2005, with emphasis given to randomized controlled trials of site-specific disease. Survival, rate of larynx preservation, and toxicities were the principal outcomes assessed. The guideline underwent internal review and approval by the Panel, as well as external review by additional experts, members of the American Society of Clinical Oncology (ASCO) Health Services Committee, and the ASCO Board of Directors. Results: Evidence supports the use of larynx-preservation approaches for appropriately selected patients without a compromise in survival; however, no larynx-preservation approach offers a survival advantage compared with total laryngectomy and adjuvant therapy with rehabilitation as indicated. Recommendations: All patients with T1 or T2 laryngeal cancer, with rare exception, should be treated initially with intent to preserve the larynx. For most patients with T3 or T4 disease without tumor invasion through cartilage into soft tissues, a larynx-preservation approach is an appropriate, standard treatment option, and concurrent chemoradiotherapy therapy is the most widely applicable approach. To ensure an optimum outcome, special expertise and a multidisciplinary team are necessary, and the team should fully discuss with the patient the advantages and disadvantages of larynx-preservation options compared with treatments that include total laryngectomy.

UR - http://www.scopus.com/inward/record.url?scp=33747032033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747032033&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.07.4559

DO - 10.1200/JCO.2006.07.4559

M3 - Article

C2 - 16832122

AN - SCOPUS:33747032033

VL - 24

SP - 3693

EP - 3704

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 22

ER -